R&D Head Ehlers Bows Out As Confidence In Biogen's Pipeline Suffers From Setbacks
EVP Michael Ehlers swaps public company scrutiny for early-stage, venture-funded opportunities at Apple Tree Partners and Limelight Bio, while CMO and longtime Biogen executive Alfred Sandrock reclaims R&D oversight role.
You may also be interested in...
The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
An About Face As Biogen Says It Will File Aducanumab In Alzheimer’s
Biogen surprised investors with news that it will file aducanumab with the FDA based on data from more patients treated at the highest dose than in the interim futility analysis that led to termination of two Phase III studies in March.